

Results of Annual General Meeting

Valencia, CA, USA, and Melbourne, Australia, 30 November 2018 — AVITA Medical (ASX – AVH, OTCQX: AVMXY), in accordance with ASX Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act, advise details of the resolutions and the proxies received in respect of each resolution, which are set out in the attached proxy summary.

###

ABOUT AVITA MEDICAL LIMITED

AVITA Medical is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Medical's patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patient's own skin. The medical devices work by preparing a REGENERATIVE EPIDERMAL SUSPENSION™ (RES™), an autologous suspension comprised of the patient's skin cells necessary to regenerate natural healthy epidermis. This autologous suspension is then sprayed onto the areas of the patient requiring treatment.

AVITA Medical's first U.S. product, the RECELL® System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018. The RECELL System is indicated for use in the treatment of acute thermal burns in patients 18 years and older. The RECELL System produces Spray-On Skin™ Cells using a small amount of a patient's own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from randomized, controlled clinical trials conducted at major U.S. burn centers and real-world use in more than 7,000 patients globally, reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings. Healthcare professionals should read the INSTRUCTIONS FOR USE - RECELL® Autologous Cell Harvesting Device for a full description of important safety information including contraindications, warnings and precautions.

In international markets outside of Europe, our portfolio is marketed under the RECELL System brand to promote skin healing in a wide range of applications including burns, chronic wounds and aesthetics. The

RECELL System is TGA-registered in Australia, CFDA-cleared in China, and received CE-mark approval in Europe.

To learn more, visit www.avitamedical.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This letter includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “intend,” “could,” “may,” “will,” “believe,” “estimate,” “look forward,” “forecast,” “goal,” “target,” “project,” “continue,” “outlook,” “guidance,” “future,” other words of similar meaning and the use of future dates. Forward-looking statements in this letter include, but are not limited to, statements concerning, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth in our business, and our ability to achieve our key strategic, operational and financial goal. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward-looking statement contained in this letter is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the timing of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, economic or political conditions outside of the company’s control. Investors should not place considerable reliance on the forward-looking statements contained in this letter. Investors are encouraged to read our publicly available filings for a discussion of these and other risks and uncertainties. The forward-looking statements in this letter speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements.

FOR FURTHER INFORMATION:

<p>US Media Syneos Health Public Relations Christian Pflaumer Phone +1-212-229-8412 Nicole Beckstrand Phone +1-858-431-9611 AVITAMedicalTeam@syneoshealth.com</p> <p>OUS Media Monsoon Communications Sarah Kemter Phone +61 (0)3 9620 3333 Mobile +61 (0)407 162 530 sarahk@monsoon.com.au</p>	<p>Investors: Westwicke Partners Caroline Corner Phone +1-415-202-5678 caroline.corner@westwicke.com</p> <p>AVITA Medical Ltd Dale A. Sander Chief Financial Officer Phone +1-661-367-9178 dsander@avitamedical.com</p>
---	---

AVITA MEDICAL LIMITED
ANNUAL GENERAL MEETING
Friday, 30 November 2018
Voting Results

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth).

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 ADOPTION OF REMUNERATION REPORT	Ordinary	442,457,657 93.69%	24,149,032 5.11%	5,660,238 1.20%	2,761,559	454,044,661 94.95%	24,149,032 5.05%	2,761,809	Carried
2 RE-ELECTION OF DIRECTOR LOU PANACCIO	Ordinary	457,371,703 96.62%	10,624,074 2.24%	5,386,027 1.14%	12,146,682	468,985,692 97.78%	10,624,074 2.22%	12,146,682	Carried
3 APPROVAL OF 10% PLACEMENT CAPACITY	Special	455,766,028 94.44%	21,362,696 4.43%	5,421,813 1.13%	2,977,949	467,415,803 95.63%	21,362,696 4.37%	2,977,949	Carried
4 APPROVE ISSUE OF OPTIONS TO DR MICHAEL PERRY	Ordinary	437,415,623 90.42%	40,902,474 8.46%	5,386,027 1.12%	1,824,362	448,967,958 91.65%	40,902,474 8.35%	1,824,362	Carried
5 APPROVAL OF THE EMPLOYEE SHARE PLAN	Ordinary	451,438,542 93.54%	25,716,724 5.33%	5,412,710 1.12%	2,960,510	462,778,268 94.74%	25,716,724 5.26%	2,960,510	Carried

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.